Oral Hyposensitization to Poison Ivy and Poison Oak

James Marks, Joseph J. Trautlein, William L. Epstein, Donna M. Laws, Guillermo R. Sicard

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

• We evaluated the safety and efficacy of a 1:1 mixture of pentadecylcatechol (PDC) and heptadecylcatechol (HDC) diacetate in reducing hypersensitivity to poison ivy and poison oak. The study was double-blind, parallel, randomized, and placebo controlled. The 44 subjects receiving the active drug ingested a cumulative dose of 306.5 mg over a five-week period. Subsequently, 14 patients were continued on a maintenance phase, ingesting an additional 960 mg of drug. The PDC-HDC diacetate was well tolerated, with no significant side effects. Evaluation of efficacy compared poststudy and prestudy reactions to patch tests using urushiol in doses of 0.025, 0.05, 0.125, 0.25, and 0.5 μg applied to the forearm. The results indicated that the induction phase as well as the maintenance phase did not induce a statistically significant hyposensitivity to urushiol, and we were thus unable to decrease sensitivity to poison ivy and poison oak in humans using orally ingested PDC-HDC diacetate.

Original languageEnglish (US)
Pages (from-to)476-478
Number of pages3
JournalArchives of Dermatology
Volume123
Issue number4
DOIs
StatePublished - Jan 1 1987

Fingerprint

Toxicodendron
Maintenance
Patch Tests
Double-Blind Method
Forearm
Pharmaceutical Preparations
Hypersensitivity
Placebos
Safety
3-heptadecylcatechol

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Marks, J., Trautlein, J. J., Epstein, W. L., Laws, D. M., & Sicard, G. R. (1987). Oral Hyposensitization to Poison Ivy and Poison Oak. Archives of Dermatology, 123(4), 476-478. https://doi.org/10.1001/archderm.1987.01660280078027
Marks, James ; Trautlein, Joseph J. ; Epstein, William L. ; Laws, Donna M. ; Sicard, Guillermo R. / Oral Hyposensitization to Poison Ivy and Poison Oak. In: Archives of Dermatology. 1987 ; Vol. 123, No. 4. pp. 476-478.
@article{3c6ffc5c8abc4de7ad9142cedf886aaf,
title = "Oral Hyposensitization to Poison Ivy and Poison Oak",
abstract = "• We evaluated the safety and efficacy of a 1:1 mixture of pentadecylcatechol (PDC) and heptadecylcatechol (HDC) diacetate in reducing hypersensitivity to poison ivy and poison oak. The study was double-blind, parallel, randomized, and placebo controlled. The 44 subjects receiving the active drug ingested a cumulative dose of 306.5 mg over a five-week period. Subsequently, 14 patients were continued on a maintenance phase, ingesting an additional 960 mg of drug. The PDC-HDC diacetate was well tolerated, with no significant side effects. Evaluation of efficacy compared poststudy and prestudy reactions to patch tests using urushiol in doses of 0.025, 0.05, 0.125, 0.25, and 0.5 μg applied to the forearm. The results indicated that the induction phase as well as the maintenance phase did not induce a statistically significant hyposensitivity to urushiol, and we were thus unable to decrease sensitivity to poison ivy and poison oak in humans using orally ingested PDC-HDC diacetate.",
author = "James Marks and Trautlein, {Joseph J.} and Epstein, {William L.} and Laws, {Donna M.} and Sicard, {Guillermo R.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1001/archderm.1987.01660280078027",
language = "English (US)",
volume = "123",
pages = "476--478",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "4",

}

Marks, J, Trautlein, JJ, Epstein, WL, Laws, DM & Sicard, GR 1987, 'Oral Hyposensitization to Poison Ivy and Poison Oak', Archives of Dermatology, vol. 123, no. 4, pp. 476-478. https://doi.org/10.1001/archderm.1987.01660280078027

Oral Hyposensitization to Poison Ivy and Poison Oak. / Marks, James; Trautlein, Joseph J.; Epstein, William L.; Laws, Donna M.; Sicard, Guillermo R.

In: Archives of Dermatology, Vol. 123, No. 4, 01.01.1987, p. 476-478.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Oral Hyposensitization to Poison Ivy and Poison Oak

AU - Marks, James

AU - Trautlein, Joseph J.

AU - Epstein, William L.

AU - Laws, Donna M.

AU - Sicard, Guillermo R.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - • We evaluated the safety and efficacy of a 1:1 mixture of pentadecylcatechol (PDC) and heptadecylcatechol (HDC) diacetate in reducing hypersensitivity to poison ivy and poison oak. The study was double-blind, parallel, randomized, and placebo controlled. The 44 subjects receiving the active drug ingested a cumulative dose of 306.5 mg over a five-week period. Subsequently, 14 patients were continued on a maintenance phase, ingesting an additional 960 mg of drug. The PDC-HDC diacetate was well tolerated, with no significant side effects. Evaluation of efficacy compared poststudy and prestudy reactions to patch tests using urushiol in doses of 0.025, 0.05, 0.125, 0.25, and 0.5 μg applied to the forearm. The results indicated that the induction phase as well as the maintenance phase did not induce a statistically significant hyposensitivity to urushiol, and we were thus unable to decrease sensitivity to poison ivy and poison oak in humans using orally ingested PDC-HDC diacetate.

AB - • We evaluated the safety and efficacy of a 1:1 mixture of pentadecylcatechol (PDC) and heptadecylcatechol (HDC) diacetate in reducing hypersensitivity to poison ivy and poison oak. The study was double-blind, parallel, randomized, and placebo controlled. The 44 subjects receiving the active drug ingested a cumulative dose of 306.5 mg over a five-week period. Subsequently, 14 patients were continued on a maintenance phase, ingesting an additional 960 mg of drug. The PDC-HDC diacetate was well tolerated, with no significant side effects. Evaluation of efficacy compared poststudy and prestudy reactions to patch tests using urushiol in doses of 0.025, 0.05, 0.125, 0.25, and 0.5 μg applied to the forearm. The results indicated that the induction phase as well as the maintenance phase did not induce a statistically significant hyposensitivity to urushiol, and we were thus unable to decrease sensitivity to poison ivy and poison oak in humans using orally ingested PDC-HDC diacetate.

UR - http://www.scopus.com/inward/record.url?scp=84943670240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943670240&partnerID=8YFLogxK

U2 - 10.1001/archderm.1987.01660280078027

DO - 10.1001/archderm.1987.01660280078027

M3 - Article

C2 - 2950827

AN - SCOPUS:84943670240

VL - 123

SP - 476

EP - 478

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 4

ER -